Sugi Predict

Sugi Predict / Compounds / SCHEMBL25293192

SCHEMBL25293192

SCHEMBL25293192

BrCC(Br)=Cc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FBP1 P09467 3/20 0.45
▸ AKR1C3 P42330 1/20 0.45
▸ ALDH1A1 P00352 2/20 0.40
▸ TSHR P16473 1/20 0.40
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ AKR1C1 Q04828 1/20 0.39
▸ ESR1 P03372 1/20 0.39
▸ RECQL P46063 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ PTPN1 P18031 1/20 0.38
▸ GSK3B P49841 1/20 0.38
▸ HTT P42858 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ MITF O75030 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ PAX8 Q06710 1/20 0.38
▸ NR1I2 O75469 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25293191 1.00 FBP1 (0.45) FBP1AKR1C3ALDH1A1TSHRCYP3A4
SCHEMBL4631524 0.81 FBP1 (0.45) FBP1AKR1C3ALDH1A1TSHRCYP3A4
SCHEMBL4631523 0.81 FBP1 (0.45) FBP1AKR1C3ALDH1A1TSHRCYP3A4
SCHEMBL9709645 0.81 FBP1 (0.45) FBP1AKR1C3ALDH1A1TSHRCYP3A4
SCHEMBL31593396 0.79 FBP1 (0.44) FBP1AKR1C3ALDH1A1TSHRCYP3A4
SCHEMBL1241929 0.79 CYP3A4 (0.57) FBP1AKR1C3ALDH1A1TSHRCYP3A4
SCHEMBL14604985 0.79 AKR1C3 (0.48) FBP1AKR1C3ALDH1A1TSHRCYP3A4
SCHEMBL4706024 0.79 AKR1C3 (0.48) FBP1AKR1C3ALDH1A1TSHRCYP3A4
SCHEMBL29054963 0.79 FBP1 (0.44) FBP1AKR1C3ALDH1A1TSHRCYP3A4
SCHEMBL1309275 0.77 FBP1 (0.42) FBP1AKR1C3ALDH1A1TSHRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12465643-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2025-11-11 — — US disclosed
US-20250319187-A1 RAS INHIBITORS REVOLUTION MEDICINES INC (US) 2025-10-16 — — US disclosed
US-12409225-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2025-09-09 — — US disclosed
US-12403196-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2025-09-02 — — US disclosed
US-20250255964-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2025-08-14 — — US disclosed
US-20250242029-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT 2025-07-31 — — US disclosed
US-20250195662-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2025-06-19 — — US disclosed
US-20250195521-A1 USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS Revolution Medicines, Inc. 2025-06-19 — — US disclosed
US-20250186590-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2025-06-12 — — US disclosed
US-12280113-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2025-04-22 — — US disclosed
CN-117683049-A Indole derivatives as RAS inhibitors for the treatment of cancer 锐新医药公司 2024-03-12 — — CN disclosed
EP-4214209-A1 INDOLE DERIVATIVES AS RAS INHIBITORS IN THE TREATMENT OF CANCER Revolution Medicines, Inc. (US) 2023-07-26 — — EP disclosed
US-20230226186-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-20 — — US disclosed
CN-116457358-A Indole derivatives as RAS inhibitors for the treatment of cancer 锐新医药公司 2023-07-18 — — CN disclosed
EP-4208261-A1 USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS Revolution Medicines, Inc. (US) 2023-07-12 — — EP disclosed
US-11690915-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2023-07-04 — — US disclosed
CN-116209438-A Treatment of malignant diseases with SHP2 mutations using SOS1 inhibitors 锐新医药公司 2023-06-02 — — CN disclosed
US-20220105185-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2022-04-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250195662-A1 RAS INHIBITORS KRAS, NRAS, HRAS FBP1 2176/4885AKR1C3 4025/4885ALDH1A1 4437/4885
US-20250186590-A1 RAS INHIBITORS KRAS, NRAS, HRAS FBP1 2176/4885AKR1C3 4025/4885ALDH1A1 4437/4885
US-20250319187-A1 RAS INHIBITORS KRAS, NRAS, HRAS FBP1 2176/4885AKR1C3 4025/4885ALDH1A1 4437/4885
US-20250195521-A1 USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS SOS1, PPM1D, PTPN1 FBP1 596/4885AKR1C3 4698/4885ALDH1A1 4135/4885
US-20250255964-A1 RAS INHIBITORS KRAS, NRAS, HRAS FBP1 2176/4885AKR1C3 4025/4885ALDH1A1 4437/4885
US-11690915-B2 Ras inhibitors KRAS, NRAS, HRAS FBP1 2176/4885AKR1C3 4025/4885ALDH1A1 4437/4885
US-12403196-B2 Ras inhibitors KRAS, NRAS, HRAS FBP1 2176/4885AKR1C3 4025/4885ALDH1A1 4437/4885
US-12465643-B2 Ras inhibitors KRAS, NRAS, HRAS FBP1 2176/4885AKR1C3 4025/4885ALDH1A1 4437/4885
US-20230226186-A1 RAS INHIBITORS KRAS, NRAS, HRAS FBP1 2176/4885AKR1C3 4025/4885ALDH1A1 4437/4885
US-20250242029-A1 RAS INHIBITORS KRAS, NRAS, HRAS FBP1 2176/4885AKR1C3 4025/4885ALDH1A1 4437/4885
US-20220105185-A1 RAS INHIBITORS KRAS, NRAS, HRAS FBP1 2176/4885AKR1C3 4025/4885ALDH1A1 4437/4885
US-12280113-B2 Ras inhibitors KRAS, NRAS, HRAS FBP1 2176/4885AKR1C3 4025/4885ALDH1A1 4437/4885
US-12409225-B2 Ras inhibitors KRAS, NRAS, HRAS FBP1 2176/4885AKR1C3 4025/4885ALDH1A1 4437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.